The recent arrival of novel oral anticoagulants has provided important new options for venous thromboembolism (VTE) treatment and prevention.

FORBES: Xarelto Effective In Medically Ill Patients But At High Bleeding Cost

Our model assumes Xarelto captures 31% of sales among new anticoagulants in 2015 with Eliquis capturing 45% and Pradaxa only 18%.

FORBES: Analyst Says Xarelto Niche "Still Secure"

Patients receiving an acute intervention, for example in myocardial infarction, need anticoagulants and antiplatelet drugs but these increase the risk of bleeding.

FORBES: ESC Gives A Shot In the Arm To Radial Access For PCI Procedures: A New Default?

The question is whether one can find a dose that prevents thromboembolic strokes with the new generation anticoagulants at an acceptable level of bleeding.

FORBES: Pradaxa To Be Contraindicated In Patients With Mechanical Heart Valves